ERBB2 and head and neck squamous cell carcinoma: Given that HER2 and EGFR pathways have significant overlap, targeting both HER2 and EGFR simultaneously could amplify antitumor effects and reduce the likelihood of resistance development, which is a common issue with EGFR‐based therapies in HNSCC.